APOE ε4与房颤患者服用阿哌沙班时颅内出血风险
本研究基于美国All of Us研究项目,纳入2038例年龄>50岁、房颤且服用阿哌沙班、无缺血性卒中或颅内出血史的患者,随访中位2.9年。多变量Cox模型显示APOE ε4携带与颅内出血风险增加约3倍相关(HR 3.07,95%CI 1.42-6.65)。
要点
- 房颤患者服用阿哌沙班时,APOE ε4携带者颅内出血风险是非携带者的3倍。
- APOE ε4携带者颅内出血累积发生率为3.1%,非携带者为1%。
核心结论
- 在服用阿哌沙班的房颤患者中,APOE ε4携带与颅内出血风险增加约3倍相关。
研究设计与样本
- 队列研究,数据来自美国All of Us研究项目,纳入2038例年龄>50岁、房颤且服用阿哌沙班、无缺血性卒中或颅内出血史的患者。
主要发现
- 中位随访2.9年,26例发生颅内出血,累积发生率1.5%(95%CI 1.0%-2.2%)。
- 多变量Cox模型显示APOE ε4携带与颅内出血风险增加相关(HR 3.07,95%CI 1.42-6.65)。
关键数值与推荐
- APOE ε4携带与颅内出血风险的HR为3.07(95%CI 1.42-6.65)。
临床怎么用
- 对于服用阿哌沙班的房颤患者,可考虑APOE ε4基因信息以辅助评估颅内出血风险。
- APOE ε4携带者可能需要更密切的出血监测或个体化抗凝决策。
局限性
- 需要进一步研究评估脑淀粉样血管病是否介导观察到的关联。
- 需要进一步研究评估APOE ε4信息是否改善房颤抗凝治疗的临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The APOE ε4 variant is causally linked to cerebral amyloid angiopathy and is a risk factor for intracranial hemorrhage (ICH) among warfarin-treated patients with atrial fibrillation. Nevertheless, its impact on those treated with apixaban remains unknown. OBJECTIVE: To test the hypothesis that APOE ε4 allele carriership is associated with an increased risk of ICH in patients with atrial fibrillation taking apixaban. DESIGN, SETTING, AND PARTICIPANTS: This cohort study involved data from the All of Us Research Program, a longitudinal, population-based study in the United States. Inclusion criteria were age older than 50 years, history of atrial fibrillation, and anticoagulation with apixaban. Participants with a history of ischemic stroke or ICH were excluded. Up to 3 years of follow-up data were available. Data were collected from 2017 to 2022 and analyzed from November 2023 to December 2024. EXPOSURE: APOE ε2, ε3, and ε4 were ascertained using variants rs429358 and rs7412. APOE ε4 was modeled dichotomously (noncarriers [no alleles] vs carriers [1 or 2 alleles]). MAIN OUTCOMES AND MEASURES: Incident ICH, including any new intraparenchymal, subdural, or subarachnoid hemorrhage after initiation of apixaban therapy. RESULTS: Of 413 477 All of Us participants, 2038 were eligible. Their mean (SD) age was 71 (9) years; 918 (45%) were female, 1120 (55%) were male, and 1710 (83%) had European ancestry. Among these participants, 483 (23.7%) were carriers of at least 1 APOE ε4 allele. After a median follow-up of 2.9 years, 26 participants sustained an ICH (cumulative incidence, 1.5%; 95% CI, 1.0%-2.2%), of whom 12 (cumulative incidence, 3.1%; 95% CI, 1.7%-5.3%) were carriers and 14 (cumulative incidence, 1%; 95% CI, 0.6%-1.7%) were noncarriers (P = .007). Multivariable Cox proportional hazard models confirmed this association: compared with noncarriership, APOE ε4 carriership was associated with a 3-fold increase in the risk of ICH (hazard ratio, 3.07; 95% CI, 1.42-6.65). APOE information improved the discrimination of risk prediction scores (C statistic of 0.74 and 0.68 for models with and without APOE, respectively; P = .03). CONCLUSIONS AND RELEVANCE: Further research is needed to evaluate whether cerebral amyloid angiopathy mediates the observed association and whether APOE e4 information improves clinical decision-making about anticoagulation therapy in patients with atrial fibrillation. The latter is important now that APOE information is used in clinical settings to guide antiamyloid treatment for Alzheimer disease and has been returned to millions of persons by direct-to-consumer genotyping companies.
引用
- Clocchiatti-Tuozzo S, Rivier CA, Renedo D, et al. APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban. JAMA Neurol. 2025. PMID: 40549373. doi:10.1001/jamaneurol.2025.0182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。